BioMarin BMRN announced that the European Medicines Agency (“EMA”) validated its Type II Variation application, seeking label expansion for Voxzogo (vosoritide) injection to treat children aged under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results